Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis.
作者信息
Nichols Derek, Boyle Theresa A, Noyes David, Latifi Kujtim, Feygelman Vladimir, Jackson Isabel, Vujaskovic Zeljko, Antonia Scott, Perez Bradford A
机构信息
Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
出版信息
J Thorac Dis. 2018 Nov;10(11):6254-6260. doi: 10.21037/jtd.2018.10.01.
Abstract
摘要
相似文献
1
Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis.在肺炎和纤维化的临床前小鼠模型中评估联合抗PD-1免疫疗法和放射疗法。
J Thorac Dis. 2018 Nov;10(11):6254-6260. doi: 10.21037/jtd.2018.10.01.
2
Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma.联合抗程序性死亡-1免疫疗法与放射疗法治疗肾细胞癌中的肺炎
Cureus. 2018 Dec 18;10(12):e3748. doi: 10.7759/cureus.3748.
3
Radiation Therapy Plus Anti-Programmed Death Ligand 1 Immunotherapy: A Review on Overall Survival.放射治疗联合抗程序性死亡配体1免疫疗法：总生存期综述
Radiol Technol. 2016 Sep;88(1):123-8.
4
Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.预先存在的肺纤维化是非小细胞肺癌患者抗 PD-1 相关肺炎的一个危险因素：一项回顾性分析。
Lung Cancer. 2018 Nov;125:212-217. doi: 10.1016/j.lungcan.2018.10.001. Epub 2018 Oct 3.
5
Radiation Recall Pneumonitis Induced by Anti-PD-1 Blockade: A Case Report and Review of the Literature.抗程序性死亡蛋白1（PD-1）阻断剂诱发的放射性肺炎再发：一例病例报告及文献综述
Front Oncol. 2020 Apr 28;10:561. doi: 10.3389/fonc.2020.00561. eCollection 2020.
6
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.胶质母细胞瘤中联合基因介导的细胞毒性免疫治疗和免疫检查点阻断的临床前研究。
Neuro Oncol. 2018 Jan 22;20(2):225-235. doi: 10.1093/neuonc/nox139.
7
Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.利用 Hu-PBL-NSG 肺癌模型评估免疫肿瘤药物的有前景的临床前平台。
Lung Cancer. 2019 Jan;127:112-121. doi: 10.1016/j.lungcan.2018.11.035. Epub 2018 Nov 27.
8
Mitigation of Radiation-Induced Lung Pneumonitis and Fibrosis Using Metformin and Melatonin: A Histopathological Study.二甲双胍和褪黑素减轻放射性肺肺炎和肺纤维化：一项组织病理学研究。
Medicina (Kaunas). 2019 Jul 30;55(8):417. doi: 10.3390/medicina55080417.
9
Hsp70-Activated NK Cells in Combination With PD-1 Inhibition Significantly Increase Overall Survival in Preclinical Models of Glioblastoma and Lung Cancer.热休克蛋白 70 激活的自然杀伤细胞与 PD-1 抑制联合应用显著提高胶质母细胞瘤和肺癌的临床前模型的总生存率。
Front Immunol. 2019 Mar 22;10:454. doi: 10.3389/fimmu.2019.00454. eCollection 2019.
10
Integrin αβ-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy.整合素 αβ 靶向放射性核素治疗联合免疫检查点阻断免疫治疗协同增强抗肿瘤疗效。
Theranostics. 2019 Oct 16;9(25):7948-7960. doi: 10.7150/thno.39203. eCollection 2019.
引用本文的文献
1
EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF mutation: a case report and review of literature.EGFR/BRAF/MEK联合抑制治疗获得性BRAF突变的EGFR突变型肺腺癌患者：一例报告及文献复习
Cancer Drug Resist. 2021 Dec 1;4(4):1019-1027. doi: 10.20517/cdr.2021.98. eCollection 2021.
2
Effect of PD-1 Inhibitor Combined with X-Ray Irradiation on the Inflammatory Microenvironment and Lung Tissue Injury in Mice.PD-1抑制剂联合X射线照射对小鼠炎症微环境及肺组织损伤的影响
J Inflamm Res. 2022 Jan 26;15:545-556. doi: 10.2147/JIR.S350112. eCollection 2022.
本文引用的文献
1
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
2
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.既往放疗与帕博利珠单抗治疗非小细胞肺癌的临床活性及毒性：KEYNOTE-001 1期试验的二次分析
Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.
3
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.卡铂和培美曲塞联合或不联合帕博利珠单抗用于晚期非鳞状非小细胞肺癌：开放标签KEYNOTE-021研究的随机2期队列研究
Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.
4
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
5
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.程序性细胞死亡蛋白 1 抑制剂相关肺炎在晚期癌症患者中的发生率：系统评价和荟萃分析。
JAMA Oncol. 2016 Dec 1;2(12):1607-1616. doi: 10.1001/jamaoncol.2016.2453.
6
The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.纳武单抗治疗晚期（转移性）非小细胞肺癌的安全性和疗效。
Expert Rev Anticancer Ther. 2016 Sep;16(9):903-10. doi: 10.1080/14737140.2016.1220836. Epub 2016 Aug 22.
7
Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.伊匹单抗治疗非小细胞肺癌后根治性放疗和术后放疗的毒性
Lung Cancer. 2016 Aug;98:76-78. doi: 10.1016/j.lungcan.2016.05.014. Epub 2016 May 25.
8
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.癌症免疫治疗期间与抗程序性死亡蛋白1相关的肺炎
N Engl J Med. 2015 Jul 16;373(3):288-90. doi: 10.1056/NEJMc1505197.
9
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
10
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.放疗和双重检查点阻断激活癌症中的非冗余免疫机制。
Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.
Zotero 插件